Faster MRI could replace CT scans for liver cancer survivors

NCT ID NCT06537193

Recruiting now Diagnosis Sponsor: Asan Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a shorter, contrast-enhanced MRI scan can detect liver cancer recurrence as well as standard CT scans in people who have been cancer-free for over two years after treatment. About 455 participants will receive both scans to compare their accuracy. The goal is to find a safer screening method that reduces radiation and contrast agent risks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: gadoxetic acid (Primovist)
What this could lead to: If successful, this could lead to a safer, faster, and equally effective way to monitor liver cancer survivors for recurrence, reducing radiation exposure and contrast agent risks.
What could go wrong: This is a diagnostic accuracy study, not a treatment trial. The abbreviated MRI may not detect all recurrences, and results may not apply to all patient groups or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Asan Medical Center
RECRUITING

Seoul, Songpa-gu , 88, Olympic-ro 43-gil, 05505, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.